Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Companies / Leal Therapeutics

Leal Therapeutics

Series AUS
Facts
Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
1
Disclosed raised
$30.0Msum of rounds with a disclosed amount only
Named investors
7
Financing history
1 rounds
  1. Aug 17, 2026
    Series A Extension · $30.0M (disclosed)
    Eli Lilly (participant)Euclidean Capital (participant)SV Health Investors' Dementia Discovery Fund (participant)Chugai Venture Fund (participant)Alexandria Venture Investments (participant)Newpath Management, L.P. (participant)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “Leal Therapeutics Announces $30 Million Series A Extension and Initiation of Phase 1b/2a Clinical Trial of LTX-001 in Schizophrenia”
Investors on record
7 edges
People
0 officers, 0 directors
No officer or director on record.
Timeline
1
  1. Aug 17, 2026
    Leal Therapeutics announced Series A Extension of $30,000,000
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
3 observations
Every observation on this company